[Therapeutic vitrectomy in uveitis: current status and recommendations].
With the advent of modern vitreoretinal surgical techniques, the spectrum for surgical intervention in various forms of uveitis has been notably expanded. Removal of optically relevant vitreous opacities, improvement of secondary macular edema, delamination of epiretinal membranes, and release of traction in the presence of abnormal vitreoretinal adhesions represent indications for vitreoretinal procedures in uveitis patients. Furthermore, retinal and choroidal biopsies may be obtained if the precise etiology is unknown. This in turn offers the opportunity to better target pharmacological interventions. Combined cataract surgery or intravitreal implantation of drug devices may also be of therapeutic benefit. So far no prospective, controlled clinical trials have been performed to precisely evaluate the role of pars plana vitrectomy (ppV) as a single or combined surgical procedure in patients with intraocular inflammation. Inconsistent data exist regarding prognostic determinants and the role of perioperative immunosuppression. Here, the current knowledge on the subject is reviewed and critically discussed, and recommendations for patient management are given. Further studies are needed.
Becker
M D
MD
Interdiszplinäres Uveitiszentrum Heidelberg, Heidelberg. Matthias.Becker@urz.uni-heidelberg.de
Harsch
N
N
Zierhut
M
M
Davis
J L
JL
Holz
F G
FG
D003131:Combined Modality Therapy / Q000379:methods; D005060:Europe; D017408:Guidelines as Topic / Q000592:standards; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D005791:Patient Care / Q000379:methods; D018579:Patient Selection; D010818:Practice Patterns, Physicians' / Q000592:standards / Q000639:trends; D016896:Treatment Outcome; D014481:United States; D014605:Uveitis / Q000175:diagnosis* / Q000601:surgery* / Q000628:therapy; D014821:Vitrectomy / Q000379:methods* / Q000639:trends*
D007166:Immunosuppressive Agents